Countdown to the Event

See you in 90 days 8 hours 19 minutes
  • 90
    Days
  • 8
    Hours
  • 19
    Minutes
  • 21
    Seconds
Register By
January 29, 2027 4:59 PM

 

Elevate Your Impact in Hematologic Oncology!

 

Join us for an event that unites community-based providers and academic oncologists, all dedicated to enhancing the care and outcomes of patients with hematologic malignancies. This activity will explore the latest treatment options and medical advancements aimed at reducing cancer-related deaths. You’ll gain insights into groundbreaking therapies like CAR T-cell therapy, novel immunotherapies, and targeted agents that represent the forefront of managing both newly diagnosed and relapsed blood cancers.


Stay informed with the latest scientific updates and innovative strategies that directly impact your practice. Participants will engage in discussions about rapidly evolving treatment landscapes, evaluate critical considerations for sequencing novel agents, and refine practice paradigms that elevate patient care across all treatment settings.


This is your chance to enhance your knowledge of best practices for treating hematologic cancers while learning when to refer patients for specialized quaternary care and clinical trial opportunities. Don’t miss out on this chance to stay ahead in your field—register today to secure your spot and transform your approach to patient management!

Target Audience
This conference is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and all healthcare professionals dedicated to the treatment of hematologic cancers.

Learning Objectives
· Illustrate how new data presented at the 2026 Annual Meeting of the American Society of Hematology can apply to clinical practice;

· Discuss emerging novel treatment strategies, the role of targeted agents in therapeutic paradigms for patients with lymphoid malignancies, and available clinical trial options and other approaches for patients with relapsed/refractory disease;

· Discuss optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed/refractory disease;

· Interpret emerging clinical trial data in the context of cellular therapies for hematologic malignancies and its place in evolving hematologic malignancy treatment standards;

· Evaluate available treatments for the care of patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for evidence-based care of both newly diagnosed and relapsed/refractory cases; 

· Discuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, bispecific antibodies targeting BCMA and GPRC5D, and dual-antigen targeting strategies; 

· Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common classic hematologic disorders, including newly approved therapeutic classes such as menin inhibitors and next-generation BCL-2 inhibitors;

· Discuss international trends in the care of hematologic malignancies.

Accreditation Statements

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 6.75 contact hours.

 

Pharmacy Credit
Pinnacle Conference, LLC is providing ACPE continuing pharmacy education credit for this activity. To receive CPE credit through CPE Monitor, please ensure you have provided your NABP ePID number and DOB appropriately. If you are unsure or would like to confirm, please contact ce@learnatpinnacle.com within 60 days of completing the activity.

 

American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.